The most frequent adverse events in the brentuximab vedotin group were peripheral sensory neuropathy ( @ -LSB- @ % -RSB- of @ patients vs @ -LSB- @ % -RSB- of @ patients in the placebo group ) and neutropenia ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- patients ) .